Evidence map›Paper›PMID 39331322›Full record

ReviewCurrent reviews in musculoskeletal medicine2024

The Effect of Platelet Dose on Outcomes after Platelet Rich Plasma Injections for Musculoskeletal Conditions: A Systematic Review and Meta-Analysis.

William Berrigan, Frances Tao, Joel Kopcow, Anna L Park, Isabel Allen, Peggy Tahir, Aakash Reddy, Zachary Bailowitz

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current reviews in musculoskeletal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07491367 (Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07491367 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems

TypeinterventionalSponsorUniversity of California, San FranciscoRan2026 to 2028Enrolled20ConditionsKnee Osteoarthristis, Cartilage Damage, Platelet Rich Plasma, Platelet Rich Plasma InjectionArmsPlatelet Rich Plasma, Emcyte PurePRP Supraphysiologic Concentrating System, APEX Biologix XCELL PRP System
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Use of platelet-rich plasma in rheumatic diseases.Rheumatology international · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

William BerriganDepartment of Orthopaedic Surgery, University of California, 1500 Owens Street, San Francisco, 94158, USA. bill.berrigan@ucsf.edu.
Frances TaoDepartment of Orthopaedic Surgery, University of California, 1500 Owens Street, San Francisco, 94158, USA.
Joel KopcowSchool of Medicine, University of California, San Francisco, USA.
Anna L ParkSchool of Medicine, University of California, San Francisco, USA.
Isabel AllenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Peggy TahirSchool of Medicine, University of California, San Francisco, USA.
Aakash ReddyUniversity of California, Berkeley, CA, USA.
Zachary BailowitzDepartment of Orthopaedic Surgery, University of California, 1500 Owens Street, San Francisco, 94158, USA.

Funding

Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
NCATS NIH HHS UL1 TR001872
6 · The paper itself

Abstract

purpose of reviewThis study aims to systematically review platelet dosage in platelet rich plasma (PRP) injections for common musculoskeletal conditions. RECENT

findingsNotable heterogeneity exists in the literature regarding platelet dosage. Clinical studies indicate that a higher dosage may lead to improved outcomes concerning pain relief, functional improvement, and chondroprotection in knee osteoarthritis (OA). However, the impact of dosing on other musculoskeletal pathologies remains uncertain. Our investigation identifies a potential dose-response relationship between platelet dose and PRP effectiveness for knee OA treatment, pinpointing an optimal threshold of greater than 10 billion platelets for favorable clinical outcomes. Notably, this effect appears more pronounced for functional outcomes than for pain relief. For other conditions, a lower dosage may suffice, although the existing literature lacks clarity on this matter. PRP dosage may significantly influence treatmentoutcomes, particularly in knee OA. Further research is warranted to elucidate optimal dosages for varying conditions.

Indexed as

Osteoarthritis (OA)Platelet dosagePlatelet dosingPlatelet rich plasma (PRP)Tendinopathy

Identifiers

PMID39331322
PMCPMC11652557

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.